

Evonik wins Asia–Pacific Bioprocessing Excellence Award for Cell Culture Solutions

13 April 2023

- The Asia–Pacific Bioprocessing Excellence Awards celebrate the latest biopharmaceutical technologies
- Evonik recognized for high–quality cell culture solutions
- Award underscores company’s commitment to driving innovation in the sector

Main press contact

Julia Born
Head of Market Communications
Health Care
Phone + 49 6151 18–4984
julia1.born@evonik.com

Alternative press contact

Dr. Jürgen Krauter
Head of Market Communications Evonik
Phone +49 6181 59–6847
juergen.krauter@evonik.com

Essen, Germany. Evonik has been honored in the Asia–Pacific Bioprocessing Excellence Awards (ABEA) for its innovative Cell Culture Solutions portfolio. The company won the award for Best New Bioprocessing Supplier in Upstream Processing, in recognition of its high–quality cell culture solutions for pharmaceutical and biotech companies.

Part of the B2B and marketing intelligence company IMAPAC’s BioPharma Awards, the ceremony, which took place on March 15, celebrates outstanding achievements in the Asian bioprocessing industry. The awards applaud exceptional leaders, organizations and technologies that facilitate innovation and best practice in manufacturing in the region.

“We are honored to have been recognized by the Asia–Pacific Biopharma community for our pioneering work to address cell culture media and bioprocessing challenges, to help improve processes and performance,” said Shirley Qi, president Southeast Asia, Australia & New Zealand/head of Nutrition & Care Asia Pacific at Evonik.

Evonik’s extensive Cell Culture Solutions portfolio combines considerable development expertise and manufacturing capabilities to provide highly defined and pure cell culture ingredients for use in a wide range of applications, from biopharmaceutical R&D and manufacturing to medicinal purposes.

“This award underscores our commitment to providing first–class solutions to our customers. We will continue to push the boundaries of biopharmaceutical technology to drive the industry forward,” said Spandan Mishra, associate director business

Evonik Industries AG

Rellinghauser Straße 1–11
45128 Essen
Germany
Phone +49 201 177–01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Maik Schuh

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

development for biopharma solutions at Evonik Health Care for Asia Pacific.

Evonik's solutions include the cQrex® portfolio of peptides which address specific amino acid limitations to improve stability and solubility, enabling optimal productivity and enhancing performance in biopharma cell culture media.

Evonik's Health Care business line is a global innovation hub to the world's leading pharma and biotech companies. By leveraging six decades of industry leadership, the company provides the biopharma market with high-quality cell culture solutions including amino acids, peptides, plant-based lipids and other non-animal-derived performance boosters.

The ABEA awards ceremony was held in conjunction with the 10th annual Biologics Manufacturing Asia 2023 conference.

Further Information

Find out more about Evonik's Cell Culture Solutions
<https://healthcare.evonik.com/en/biopharma/cell-culture>

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.